Aranda Pharma
Novel treatment for hair loss and acne
ADA-308 is a highly potent novel drug candidate targeting the underserved androgenetic alopecia (AGA) market while offering opportunity for acne as a second indication. The next generation pure antiandrogen entering regulatory phase shows excellent efficacy in preclinical studies over evidence-based treatment standards and other new generation pipeline products while demonstrating clean safety profile.
ADA-308 for androgenetic alopecia
Androgenetic alopecia, AGA, is the most common type of hair loss among both men and women. It has a distinctive pattern of progression hence it is also called pattern hair loss. As the name implies androgens are the major contributors to the development of this condition making androgen targeting therapies an effective medical treatment option. The current treatments are handicapped by systemic antiandrogenic side effects. ADA-308 as a topically applied locally acting highly potent antiandrogen with no systemic effects in preclinical models is a promising treatment option for AGA.
ADA-308 for acne
Acne is a multi-factorial disease in which androgen induced excess sebum production is in the origin of the disease. Thus, it is surprising that androgen targeting therapies are underrepresented medical treatment option in acne. ADA-308 addresses this need by providing a highly potent, locally acting antiandrogen for reduction of skin oiliness in acne and a much-needed complementary treatment option to be combined with other acne medications in future.
